The MOVE-study: Morning Versus Evening Administration of 500 mcg Roflumilast Once Daily for 6 Weeks in Patients With Asthma

Trial Profile

The MOVE-study: Morning Versus Evening Administration of 500 mcg Roflumilast Once Daily for 6 Weeks in Patients With Asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Oct 2016

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms MOVE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 04 May 2012 Company added (Takeda Global Research and Development Center) as reported by ClinicalTrials.gov.
    • 24 Aug 2007 The expected completion date for this trial is now 1 Aug 2005.
    • 30 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top